INmune Bio, Inc. (NASDAQ:INMB) Shares Acquired by Two Sigma Investments LP

Two Sigma Investments LP lifted its stake in shares of INmune Bio, Inc. (NASDAQ:INMB) by 444.8% during the 4th quarter, HoldingsChannel reports. The firm owned 66,384 shares of the company’s stock after purchasing an additional 54,200 shares during the quarter. Two Sigma Investments LP’s holdings in INmune Bio were worth $310,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wells Fargo & Company MN boosted its holdings in shares of INmune Bio by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after purchasing an additional 2,155 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new position in shares of INmune Bio during the 4th quarter worth approximately $48,000. JPMorgan Chase & Co. boosted its holdings in shares of INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock worth $53,000 after purchasing an additional 5,461 shares during the last quarter. Mariner LLC acquired a new position in shares of INmune Bio during the 4th quarter worth approximately $65,000. Finally, Financial Advocates Investment Management boosted its holdings in shares of INmune Bio by 14.8% during the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after purchasing an additional 2,000 shares during the last quarter. 12.72% of the stock is currently owned by institutional investors and hedge funds.

INmune Bio Stock Performance

Shares of INmune Bio stock opened at $7.88 on Wednesday. The firm has a market capitalization of $181.11 million, a price-to-earnings ratio of -3.61 and a beta of 1.55. INmune Bio, Inc. has a fifty-two week low of $4.32 and a fifty-two week high of $10.50. The stock has a 50 day moving average of $7.49 and a 200 day moving average of $7.16.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The business had revenue of $0.05 million during the quarter. Analysts forecast that INmune Bio, Inc. will post -2.24 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on INMB shares. Maxim Group boosted their target price on INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Scotiabank increased their price objective on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 11th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $22.80.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.